Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

New liver cancer drug approved

  • Comment
The first systemic therapy for patients with hepatocellular carcinoma, the most common form of primary liver cancer, has been launched in the UK.

Sorafenib (Nexavar), an oral treatment that targets both the tumour cell and tumour vasculature, was approved by the European Medicines Agency last month. It is licensed for the treatment of patients with hepatocellular carcinoma, which comprises 80-90% of all the cases of primary liver tumours.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs